A hysterectomy permanently removes the uterus, ending menstruation and the physical ability to carry a pregnancy. It is classified under major gynaecological surgery and gynaecological oncology. The primary clinical goals are symptom elimination (such as relieving heavy menstrual bleeding or pelvic pain), structural correction (for pelvic organ prolapse), or curative excision of reproductive tract malignancies.

Pre-operative prophylactic antibiotics and thromboprophylaxis are administered. Under general anaesthesia, the patient is placed in the supine or lithotomy position. The surgeon gains access via abdominal incision, vaginal access, or laparoscopic/robotic ports. Uterine vessels, round ligaments, ovarian ligaments (or infundibulopelvic ligaments if oophorectomy is performed), and uterosacral ligaments are systematically divided and ligated. The uterus and cervix are removed, and the vaginal vault (cuff) is sutured closed. Hemostasis is verified, surgical sites are irrigated, and incisions are closed in layers.

Clinical benefits include permanent relief from heavy menstrual bleeding, resolution of fibroid-induced pressure symptoms, termination of adenomyosis-related pelvic pain, correction of advanced pelvic organ prolapse, and definitive oncological resection for reproductive tract cancers. According to ACOG guidelines, quality-of-life indicators improve significantly post-procedure for symptomatic benign disease.

Recovery depends on the surgical approach. Minimally invasive methods (vaginal, laparoscopic, robotic) typically require 1 to 2 weeks for initial recovery and 4 weeks for full tissue healing. Open total abdominal hysterectomy requires 2 to 3 days of hospitalization and 6 to 8 weeks of restricted activity. Full physical exertion and vaginal penetration must be avoided until cuff healing is verified at the 6-week post-operative exam.

Hysterectomy is indicated for benign and malignant conditions of the female reproductive system. Key indications include leiomyomas (uterine fibroids), severe endometriosis, adenomyosis, chronic pelvic pain refractory to conservative therapy, severe pelvic organ prolapse, intractable menorrhagia (heavy menstrual bleeding), uterine endometrial hyperplasia with atypia, and gynaecological cancers involving the endometrium, cervix, ovaries, or fallopian tubes.

Pre-procedure workup includes complete blood count, coagulation profile, blood type and crossmatch, cervical cytology, endometrial biopsy, and pelvic ultrasonography or MRI. Patients undergo medical optimization for anaemia or medical comorbidities. Fasting starts 6 to 8 hours prior to surgery. Mechanical bowel preparation or oral antibiotic preparation may be ordered selectively based on surgical approach and risk factors.

Complications are stratified by frequency and severity. Common mild risks include transient incisional pain, mild nausea, port-site bruising, and temporary urinary retention. Uncommon moderate complications include surgical site infection, vaginal cuff haematoma, urinary tract infection, and pelvic abscess. Rare serious risks include injury to adjacent structures (ureters, bladder, bowel), deep vein thrombosis, pulmonary embolism, major hemorrhage requiring blood transfusion, and vaginal cuff dehiscence.

The clinical journey begins with a comprehensive pre-operative evaluation, including pelvic imaging, endometrial sampling, and multi-disciplinary planning. On the day of surgery, general or regional anaesthesia is administered, followed by abdominal, laparoscopic, robotic, or vaginal surgical excision. Post-operative care involves a short hospital stay (0 to 3 days), pain management, early mobilization, and progressive recovery over 2 to 8 weeks, concluding with long-term hormonal and clinical follow-up.